|
2015 Journal Article Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kaehler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard and Goldinger, Simone M. (2015). Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. Plos One, 10 (10) e0139438. doi: 10.1371/journal.pone.0139438 |
|
2015 Journal Article Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanomaMatsushita, Shigeto, Kraehenbuehl, Lukas, Otsuka, Atsushi, Mihic-Probst, Daniela, Cheng, Phil, Dummer, Reinhard and Goldinger, Simone M. (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42 (9), 927-928. doi: 10.1111/1346-8138.12964 |
|
2015 Journal Article Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialRibas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F. Stephen, Schachter, Jacob, Pavlick, Anna C., Lewis, Karl D., Cranmer, Lee D., Blank, Christian U., O'Day, Steven J., Ascierto, Paolo A., Salama, April K. S., Margolin, Kim A., Loquai, Carmen, Eigentler, Thomas K., Gangadhar, Tara C., Carlino, Matteo S., Agarwala, Sanjiv S., Moschos, Stergios J., Sosman, Jeffrey A., Goldinger, Simone M., Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M., Wolchok, Jedd D., Eggermont, Alexander ... Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16 (8), 908-918. doi: 10.1016/S1470-2045(15)00083-2 |
|
2015 Journal Article Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsHecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26 (6), 1238-1244. doi: 10.1093/annonc/mdv139 |
|
2015 Journal Article Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitorGalliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512 |
|
2015 Journal Article Curing advanced melanoma by 2025Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168 |
|
2015 Journal Article A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanomaGoldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113 |
|
2015 Journal Article Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaCheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4 |
|
2014 Journal Article Basal cell carcinomas in a tertiary referral centre: a systematic analysisDreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217 |
|
2014 Journal Article Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231 |
|
2014 Journal Article Transient MEK inhibitor-associated retinopathy in metastatic melanomaUrner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R. and Goldinger, S. M. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25 (7), 1437-1441. doi: 10.1093/annonc/mdu169 |
|
2014 Journal Article To B-(RAF) or Not to BeDummer, Reinhard, Goldinger, Simone M., Widmer, Daniel, Dreier, Jil and Levesque, Mitchell P. (2014). To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 134 (5), 1200-1201. doi: 10.1038/jid.2014.62 |
|
2014 Journal Article Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kahler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25 (3), 747-753. doi: 10.1093/annonc/mdt587 |
|
2014 Journal Article Vemurafenib in patients with <i>BRAF<SUP>V600</SUP></i> mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyDummer, Reinhard, Goldinger, Simone M., Turtschi, Christian P., Eggmann, Nina B., Michielin, Olivier, Mitchell, Lada, Veronese, Luisa, Hilfiker, Paul Rene, Felderer, Lea and Rinderknecht, Jeannine D. (2014). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50 (3), 611-621. doi: 10.1016/j.ejca.2013.11.002 |
|
2014 Journal Article Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Zimmer, Lisa, Schulz, Carsten, Ugurel, Selma, Hoeller, Christoph, Kaehler, Katharina C., Schadendorf, Dirk, Hassel, Jessica C., Becker, Juergen, Hauschild, Axel and Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50 (2), 406-410. doi: 10.1016/j.ejca.2013.09.014 |
|
2014 Journal Article The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaVan Allen, Eliezer M., Wagle, Nikhil, Sucker, Antje, Treacy, Daniel J., Johannessen, Cory M., Goetz, Eva M., Place, Chelsea S., Taylor-Weiner, Amaro, Whittaker, Steven, Kryukov, Gregory V., Hodis, Eran, Rosenberg, Mara, McKenna, Aaron, Cibulskis, Kristian, Farlow, Deborah, Zimmer, Lisa, Hillen, Uwe, Gutzmer, Ralf, Goldinger, Simone M., Ugurel, Selma, Gogas, Helen J., Egberts, Friederike, Berking, Carola, Trefzer, Uwe, Loquai, Carmen, Weide, Benjamin, Hassel, Jessica C., Gabriel, Stacey B., Carter, Scott L. ... Schadendorf, Dirk (2014). The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 4 (1), 94-109. doi: 10.1158/2159-8290.CD-13-0617 |
|
2013 Journal Article RASopathic Skin Eruptions during Vemurafenib TherapyRinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721 |
|
2013 Journal Article Melanoma immunotherapy: historical precedents, recent successes and future prospectsRaaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162 |
|
2013 Journal Article The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkVoskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745 |
|
2012 Journal Article Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patientsGoldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361 |
